<?xml version="1.0" encoding="UTF-8"?>
<ref id="pone.0204870.ref018">
 <label>18</label>
 <mixed-citation publication-type="journal">
  <name>
   <surname>Gay</surname>
   <given-names>ND</given-names>
  </name>, 
  <name>
   <surname>Okada</surname>
   <given-names>CY</given-names>
  </name>, 
  <name>
   <surname>Chen</surname>
   <given-names>AI</given-names>
  </name>, 
  <name>
   <surname>Scott</surname>
   <given-names>EC</given-names>
  </name>. 
  <article-title>Targeting the programmed cell death 1 pathway in Hodgkin lymphoma: the place of nivolumab</article-title>. 
  <source>Ther Adv Hematol</source>. 
  <year>2017</year>;
  <volume>8</volume>(
  <issue>5</issue>):
  <fpage>175</fpage>â€“
  <lpage>80</lpage>. 
  <pub-id pub-id-type="doi">10.1177/2040620717695723</pub-id> ; PubMed Central PMCID: PMCPMC5407507.
  <?supplied-pmid 28473905?>
  <pub-id pub-id-type="pmid">28473905</pub-id>
 </mixed-citation>
</ref>
